Phaseline

Companies › Treeline Biosciences

Treeline Biosciences: clinical trials, targets and expected readouts

4 active drug programs in 10 registered trials: 7 Phase 1, 3 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
zeprumetostat (TLN-254)
EZH2 inhibitor
KMT2DPhase 1Lymphoma; Peripheral T Cells Lymphoma (PTCL); Bladder Urothelial Carcinoma; Follicular Lymphoma …Nov 2026
TLN-499
BCL-2 family protein inhibitor
–Phase 1Small Cell Lung Cancer ( SCLC )Aug 2030
TLN-121–Phase 1LymphomaSep 2030
TLN-372
KRAS inhibitor
–Phase 1KRAS Mutant Solid TumorsDec 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06733441zeprumetostat (TLN-254)Phase 1LymphomaOncologyNov 2026
NCT07502768zeprumetostat (TLN-254)Phase 1Extranodal NK/T-cell LymphomaOncologyDec 2027
NCT07692529zeprumetostat (TLN-254)Phase 1Large Granular Lymphocyte LeukemiaOncologyDec 2027
NCT07372352zeprumetostat (TLN-254)Phase 2Peripheral T Cells Lymphoma (PTCL)OncologyJan 2028
NCT07717242zeprumetostat (TLN-254)Phase 2Bladder Urothelial CarcinomaOncologyJun 2028
NCT07555470zeprumetostat (TLN-254)Phase 2Follicular LymphomaOncologyDec 2029
NCT07713732TLN-499Phase 1Small Cell Lung Cancer ( SCLC )OncologyAug 2030
NCT07082803TLN-121Phase 1LymphomaOncologySep 2030
NCT07082803zeprumetostat (TLN-254)Phase 1LymphomaOncologySep 2030
NCT07204340TLN-372Phase 1KRAS Mutant Solid TumorsOncologyDec 2031

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

KMT2D (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.